

平成 28 (2016) 年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版 地	出版 年	ページ	関 連
1)	川上由育、茶山一彰、田中純子、西田ルリコ	各都道府県における肝疾患対策取り組みの現状「広島県における肝炎、肝癌対策に対する取り組み」		肝臓クリニカルアップデート	医学図書出版株式会社	東京	2016	2(1), 101-105	
2)	相崎英樹、脇田隆字	C 型肝炎ウイルスの複製・増殖のメカニズム		医薬ジャーナル	医薬ジャーナル社	大阪	2016	67-70	
3)	相崎英樹、脇田隆字	肝炎ウイルス検査のすすめ		くらしの豆知識	国民生活センター	東京	2016	200-201	
4)	相崎英樹、和気健二郎、脇田隆字	ここまでわかった C 型肝炎ウイルスの感染・複製機構		Mebio	メジカルビュー社	東京	2016	4-13	
5)	島上哲朗、金子周一	C 型慢性肝疾患の薬剤治療	桑山肇	消化器の臨床	ヴァンメディカル	東京	2016	vol 19(6)	
6)	松崎靖司	薬物性肝障害・病気とくすり 2016		薬局 2016 年増刊号	南山堂	東京	2016	754-758	
7)	池上正、屋良昭一郎、松崎靖司、本多彰、宮崎照雄	消化器生活習慣病における酸化ステロールの意義・特集/胆汁酸研究の進歩と展望-これからの breakthrough を目指して-		肝胆膵	アークメディア	東京	2016	72(5) : 815-822	
8)	岩本淳一、本多彰、村上昌、池上正、松崎靖司	炎症性腸疾患における脂質・胆汁酸代謝と腸管吸収障害・特集/胆汁酸研究の進歩と展望-これからの breakthrough を目指して-		肝胆膵	アークメディア	東京	2016	72(5) : 827-831	
9)	市田隆文、渡辺光博、加川建弘、松崎靖司	座談会・胆汁酸研究の進歩と展望-これからの breakthrough を目指して-。特集/胆汁酸研究の進歩と展望-これからの breakthrough を目指して-		肝胆膵	アークメディア	東京	2016	72(5) : 935-950	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1) Murakami E, Tsuge M, Hiraga N, Kan H, Uchida T, Masaki K, Nakahara T, Ono A, Miki D, Kawaoka T, Abe H, Imamura M, Aikata H, Ochi H, Hayes CN, Akita T, <u>Tanaka J</u> , Chayama K.	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones	Journal of Infection	72(1)	91-102	2016	
2) Asao T, Oki K, Yoneda M, <u>Tanaka J</u> , Kohno N.	Hypothalamic-pituitary-adrenal axis activity is associated with the prevalence of chronic kidney disease in diabetic patients	ENDOCRINE JOURNAL	63(2)	119-126	2016	
3) Matsumoto M, Takeuchi K, <u>Tanaka J</u> , Tazuma S, Inoue K, Owaki T, Iguchi S, Maeda T.	Follow-up study of the regional quota system of Japanese medical schools and prefecture scholarship programmes: a study protocol	BMJ Open	6	e011165	2016	
4) Tada T, Kumada T, Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index	Journal of Gastroenterology	51(4)	380-389	2016	
5) Morimoto H, Ide K, Tanaka Y, Ishiyama K, Ohira M, Tahara H, Akita T, <u>Tanaka J</u> , Ohdan H.	Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation	Human Immunology	77(6)	456-63	2016	
6) Tada T, Kumada T, Toyoda H, Kirishima S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yamada T, <u>Tanaka J</u> .	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics	Journal of Hepatology	65(1)	48-56	2016	
7) Tada T, Kumada T, Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u>	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis	Liver International	36(6)	817-816	2016	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
8)	Hosoi T, Kohda T, Matsuzaki S, Ishiguchi M, Kuwamura A, Akita T, <u>Tanaka J</u> , Ozawa K.	Key role of HSP90 in leptin-induced STAT3 activation and feeding regulation	British Journal of Pharmacology	173(15)	2434-2445	2016	
9)	Harada Y, Akita T, Takenaka J, Nakamura-Kadohiro Y, <u>Tanaka J</u> , Kiuchi Y.	Reproducibility of optic disk evaluation in supine subjects with a Heidelberg Retina Tomograph II laser tomographic scanner	Clinical Ophthalmology	24(10)	1617-1622	2016	
10)	Muzembo BA, Akita T, Matsuoka T, <u>Tanaka J</u> .	Systematic review and meta-analysis of hepatitis C virus infection in the Democratic Republic of Congo.	Public Health	139	13-21	2016	
11)	Matsuoka T, Sato T, Akita T, Yanagida J, Ohge H, Kuwabara M, <u>Tanaka J</u> .	High Vaccination Coverage among Children during Influenza A(H1N1)pdm09 as a Potential Factor of Herd Immunity	International Journal of Environmental Research Public Health	13(10)	1017	2016	
12)	Shimomura M, Shinozaki K, Hinoi T, Yoshimitsu M, Kurayoshi M, Sumitani D, Ishizaki Y, Oshiro T, Kodama S, Shimizu Y, Arita M, Tokunaga M, Yoshida M, <u>Tanaka J</u> , Ohdan H; Hiroshima Surgical study group of Clinical Oncology (HiSCO).	A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study	Springer plus	5(1)	1800	2016	
13)	Akita T, <u>Tanaka J</u> , Ohisa M, Sugiyama A, Nishida K, Inoue S, Shirasaka T.	Predicting future blood supply and demand in Japan with a Markov model: application to the sex-age specific probability of blood donation.	Transfusion	56(11)	2750-2759	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
14)	Mukaida K, Hattori N, Iwamoto H, Onari Y, Nishimura Y, Kondoh K, Akita T, <u>Tanaka J</u> , Kohno N.	Mustard gas exposure and mortality among retired workers at a poisonous gas factory in Japan: A 57-year follow-up cohort study.	Occupational and Environmental Medicine	74	321-327	2017	
15)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, <u>Tanaka J</u> .	Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in CHB patients: an analysis using time-dependent ROC	Journal of Gastroenterology and Hepatology	32(2)	451-458	2017	
16)	Blach S, Zeuzem S, Manns M, et al. (<u>Tanaka J</u> , 222人中202番目)	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study	The LANCET Gastroenterology & Hepatology	2(3)	161-176	2017	
17)	Yoshimura M, Ohura N, <u>Tanaka J</u> , Ichimura S, Kasuya Y, Hotta O, Kagaya Y, Sekiyama T, Tannba M, Suzuki N.	Soft silicone foam dressing is more effective than polyurethane film dressing for preventing intraoperatively acquired pressure ulcers in spinal surgery patients: the Border Operating room Spinal Surgery (BOSS) trial in Japan	International Wound Journal	In press	doi: 10.1111/1/iwj.12696	2017	
18)	Tada T, Kumada T, Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Post-treatment levels of -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C	Hepatology Research	in press	doi:10.1111/hepr.12839	2017	
19)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Viral Eradication reduces all-Cause Mortality, Including non-Liver-Related Disease, in Patients With Progressive Hepatitis C Virus-Related Fibrosis.	J Gastroenterol Hepatol.	in press	doi:10.1111/jgh.13589	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
20)	Sugiyama A, Ohisa M, Nagashima S, Yamamoto C, Channarena C, Fujii T, Akita T, Katayama K, Kudo Y, Tanaka J	Reduced prevalence of hepatitis B surface antigen positivity among pregnant women born after the national implementation of immunoprophylaxis for babies born to hepatitis B virus-carrier mothers in Japan	Hepatology Research	in press		2017	
21)	海嶋照美、藤井紀子、永島慎太郎、片山恵子、神山道信、大熊博、田中純子	高感度 HBs 抗原測定試薬 (BLEIA 法) を用いた検出性能に関する評価	肝臓	57(1)	42-44	2016	
22)	海嶋照美、藤井紀子、松岡俊彦、坂宗和明、永島慎太郎、山本周子、Chun Channarena、山下真未、大和昌代、藤井紘子、Muzembo Basilia Andre、杉山文、大久真幸、秋田智之、片山恵子、田中純子	肝炎ウイルス検査受検状況と検査後の医療機関受診率の検討 都道府県別にみた認識受検率と非認識受検率	肝臓	57(12)	634-648	2016	
23)	田中純子	初回献血者および健診受診者集団における HBs 抗原陽性率の現状	病原微生物検出情報 (月報)	37(8)	2-5	2016	
24)	田中純子	ウイルス肝炎の最新疫学～肝炎対策と患者数の動向～	Pharma Medica	34(2)	9-13	2016	
25)	田中純子	わが国における HBV 感染の疫学	臨床消化器内科	31(3)	261-268	2016	
26)	田中純子、杉山文、大久真幸、秋田智之	疫学的視点からみた肝炎ウイルス患者に関する現状と対策	臨床病理	64(4)	465-470	2016	
27)	田中純子、大久真幸	わが国の HCV 感染の変遷と現状	臨床消化器内科	31(11)	1431-1436	2016	
28)	田中純子	わが国の HCV 感染症の現状と展望	Mebio	34(1)	14-22	2017	
29)	田中純子、片山恵子	C 型肝炎の疫学 - 最近の動向	消化器・肝臓内科	34(1)	59-65	2017	
30)	Kong L, Fujimoto A, Nakamura M, Aoyagi H, Matsuda M, Watashi K, Suzuki R, Arita M, Yamagoe S, Dohmae N, Suzuki T, Sakamaki Y, Ichinose S, Suzuki T, Wakita T, Aizaki H.	Prolactin regulatory element binding protein is involved in hepatitis C virus replication compartment by interacting with NS4B.	J Virol.	90	3093-111	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
31)	Nakajima S, Watashi K, Ohashi H, Kamisuki S, Izaguirre-Carbonell J, Kwon AT, Suzuki H, Kataoka M, Tsukuda S, Okada M, Moi ML, Takeuchi T, Arita M, Suzuki R, <u>Aizaki H</u> , Kato T, Suzuki T, Hasegawa H, Takasaki T, Sugawara F, Wakita T.	Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.	J Virol.	90	9058-74	2016	
32)	Puig-Basagoiti F, Fukuhara T, Tamura T, Ono C, Uemura K, Kawachi Y, Yamamoto S, Mori H, Kurihara T, Okamoto T, <u>Aizaki H</u> , Matsuura Y.	Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation.	J Virol.	90	8464-77	2016	
33)	Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watashi K, <u>Aizaki H</u> , Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R.	Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus.	Sci Rep.	27	28688	2016	
34)	Suzuki R, Saito K, Matsuda M, Sato M, Kanegae Y, Shi G, Watashi K, <u>Aizaki H</u> , Chiba J, Saito I, Wakita T, Suzuki T.	Single-domain intrabodies against HCV Core inhibit viral propagation and Core-induced NF- B Activation.	J Gen Virol.	97	887-92	2016	
35)	Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, <u>Aizaki H</u> , Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T.	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.	Hepatology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
36)	Kunimoto H, <u>Ikeda K</u> , Sorin Y, Fujiyama S, Kawamura Y, Kobayashi M, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H	Long-term outcomes of hepatitis-C-infected patients achieving a sustained virological response and undergoing radical treatment for hepatocellular carcinoma.	Oncology	90	167-175	2016	
37)	Kawamura Y, <u>Ikeda K</u> , Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H	Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas.	Hepatol Res		doi : 10.1111/hepr.12838	2016	
38)	<u>Ikeda K</u> , Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H	Phase 2 study lenvatinib in patients with advanced hepatocellular carcinoma.	J Gastroenterol		doi : 10.1007/s00535-016-1263-4	2016	
39)	<u>Ikeda K</u> , Kawamura Y, Kobayashi M, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H	Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma.	Hepatol Res		doi : 10.1111/hepr.12782	2016	
40)	Kawamura Y, <u>Ikeda K</u> , Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H	Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules.	Hepatol Res		doi : 10.1111/hepr.12754	2016	
41)	Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, <u>Torimura T</u>	Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study	Oncotarget	7	64400-64409	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
42)	Torimura T, Iwamoto H, Nakamura T, Abe M, Ikezono Y, Wada F, Sakaue T, Masuda H, Hashimoto O, Koga H, Ueno T, Yano H	Antiangiogenic and antitumor activities of aflibercept, a soluble VEGF receptor-1 and -2, in a mouse model of hepatocellular carcinoma	Neoplasia	18	413-424	2016	
43)	Okamura S, Sumie S, Tonan T, Nakano M, Satani M, Shimose S, Shirono T, Iwamoto H, Aino H, Niizeki T, Tajiri N, Kuromatsu R, Okuda K, Nakashima O, <u>Torimura T</u>	Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma	Dig Liver Dis	48	945-952	2016	
44)	Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K, Nakamura H, Hisatomi J, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Kuromatsu R, <u>Torimura T</u> ; DAAs Multicenter Study Group	Evaluation of resistance-associated substitutions in NS5A using direct sequence and cycleleave method and treatment outcome with Daclatasvir and Asunaprevir for chronic hepatitis C genotype 1	PLoS One	11	e0163884 (page 1-11)	2016	
45)	Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Kato J, Tokunaga S, Sugihara TA, Hara Y, <u>Hino K</u> , Murawaki Y.	A series of microRNA in the chromosome 14q32.2 maternally imprinted region related to progression of non-alcoholic fatty liver disease in a mouse model	PLoS One	11	e0154676	2016	
46)	Tamada T, Korenaga M, Yamamoto A, Higaki A, Kanki A, Nishina S, <u>Hino K</u> , Ito K.	Assessment of clinical and MRI features of de novo hypervascular HCC using gadoxetic acid enhanced MRI	Hepatology Res	Epub ahead of print	Epub ahead of print	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
47)	Koyama N, Hata J, Sato T, Tomiyama Y, <u>Hino K</u>	Assessment of hepatic fibrosis with superb microvascular imaging in hepatitis C virus-associated chronic liver diseases	Hepato Res	Epub ahead of print	Epub ahead of print	2016	
48)	Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, <u>Hino K</u> , Nishiguchi S	JSH guidelines for sarcopenia in liver disease (first edition): Recommendation from the working group for creation of sarcopenia assessment criteria in the JSH	Hepato Res	46	951-63	2016	
49)	Nakamura M, Matsumoto H, Nakashima H, Ando Y, Hirai T, Yoshida K, <u>Hino K</u>	L-carnitine supplementation improved hepatic steatosis after pancreatectomy	Pancreas	45	e7-9	2016	
50)	Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, <u>Hino K</u> , Honda M, Kaneko S, Yatsunashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang JH, Tanak E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Kojima H, Yamamoto K, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunag K, Mizokami M	Understanding of HLA-conferred susceptibility to hepatitis B infection requires HLA genotyping-based association analysis	Sci Rep	6	24767	2016	
51)	Nakamura M, Nakata K, Matsumoto H, Ohtsuka T, Yoshida K, Tokunaga S, <u>Hino K</u>	Acyl/free carnitine ratio is a risk factor for hepatic steatosis after pancreatoduodenectomy and total pancreatectomy	Pancreatology	Epub ahead of print	Epub ahead of print	2016	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連	
52)	Liu F, <u>Shimakami T</u> , Murai K, Shirasaki T, Funaki M, Honda M, Murakami S, Yi M, Tang H, Kaneko S.	Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems	Sci Rep	6	30939	2016	
53)	Yamane D, Selitsky SR, <u>Shimakami T</u> , Li Y, Zhou M, Honda M, Sethupathy P, Lemon SM.	Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants	Nucleic Acids Res	in press	in press	2017	
54)	Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Arak M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K, Aizawa Y	Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin	Hepatol Res	46	450-458	2016	
55)	Higashimura Y, Naito Y, Takagi T, Uchiyama K, Mizushima K, Ushiroda C, Ohnogi H, Kudo Y, Yasui M, Inui S, Hisada T, Honda A, <u>Matsuzaki Y</u> , Yoshikawa T	Protective effect of agaro-oligosaccharides on gut dysbiosis and colon tumorigenesis in high-fat diet-fed mice.	Am J Physiol Gastroin test Liver Physiol	310	G367-G375	2016	
56)	Miyazaki T, Nakamura Y, Ebina K, Mizushima T, Ra SG, Ishikura K, <u>Matsuzaki Y</u> , Ohmori H, Honda A	Increased N-acetyltaurine in the skeletal muscle after endurance exercise in rat	Advances in Experimental Medicine and Biology		in press	2016	
57)	Kaneko S, Ikeda K, <u>Matsuzaki Y</u> , Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K	Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study	J Gastroenterol.	51(10)	1011-21	2016	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
58)	滝川一, <u>松崎靖司</u>	シンポジウム 2: 胆道疾患と脂質代謝異常	胆道	30	52	2016	
59)	門馬匡邦, 齋藤吉史, 屋良昭一郎, 村上昌, 平山剛, 岩本淳一, 池上正, <u>松崎靖司</u>	画像を診る 鑑別診断のポイント 肝偽腫瘍の1例	消化器の臨床	19	67-70	2016	
60)	Toyoda H, <u>Kumada T</u> , Tada T, Kaneoka Y, Maeda A, Korenaga M, Mizokami M, Narimatsu H.	Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection.	Liver Int.	36(2)	293-301	2016	
61)	Hiraoka A, <u>Kumada T</u> , Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D, Tsuji K; Hiroaki Nagamatsu, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group.	Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study.	Hepatol Res.	46(6)	521-8	2016	
62)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index.	J Gastroenterol.	51(4)	380-9	2016	
63)	Tada T, <u>Kumada T</u> , Toyoda H, Ito T, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otobe K, Takahashi K.	Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma.	Ultrasound Med Biol.	41(12)	3070-78	2016	
64)	Toyoda H, Tada T, Tsuji K, Hiraoka A, Tachi Y, Itobayashi E, Takaguchi K, Senoh T, Takizawa D, Ishikawa T, <u>Kumada T</u> .	Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.	Hepatol Res.	46(8)	734-42	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
65)	Hiraoka A, <u>Kumada I</u> , Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H.	Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.	J Gastroenterol Hepatol.	31(5)	1031-6.	2016	
66)	Terashita K, Chuma M, Hatanaka Y, Hatanaka K, Mitsuhashi T, Yokoo H, Ohmura T, Ishizu H, Muraoka S, Nagasaka A, Tsuji T, Yamamoto Y, Kurauchi N, Shimoyama N, Toyoda H, <u>Kumada I</u> , Kaneoka Y, Maeda A, Ogawa K, Natsuizaka M, Kamachi H, Kakisaka T, Kamiyama T, Taketomi A, Matsuno Y, Sakamoto N.	ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.	Clin Pathol.	69(7)	593-9	2016	
67)	Chan AW, <u>Kumada T</u> , Toyoda H, Tada T, Chong CC, Mo FK, Yeo W, Johnson PJ, Lai PB, Chan AT, To KF, Chan SL.	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.	J Gastroenterol Hepatol.	31(7)	1300-6.	2016	
68)	Berhane S, Toyoda H, Tada T, <u>Kumada I</u> , Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.	Clin Gastroenterol Hepatol.	14(6)	875-886	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
69)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.	Liver Int.	36(6)	817-26	2016	
70)	Tada T, <u>Kumada T</u> , Toyoda H, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otobe K, Tsuji N.	Utility of combined gray-scale and perflubutane contrast-enhanced ultrasound for diagnosing early hepatocellular carcinomas: Comparison of well differentiated and distinctly nodular types.	Hepatol Res.	46(12)	1214-1225.	2016	
71)	Toyoda H, <u>Kumada T</u> , Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y.	Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.	J Gastroenterol.	51(7)	741-7.	2016	
72)	Toyoda H, <u>Kumada T</u> , Tada T.	Response to 'WFA(+)-M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases'.	Liver Int.	36(4)	613	2016	
73)	Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, <u>Kumada T</u> , Johnson PJ.	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.	Br J Cancer.	114(7)	744-50	2016	
74)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.	J Hepatol.	65(1)	48-56.	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
75)	Matsushima-Nishiwaki R, Toyoda H, Nagasawa T, Yasuda E, Chiba N, Okuda S, Maeda A, Kaneoka Y, <u>Kumada T</u> , Kozawa O.	Phosphorylated Heat Shock Protein 20 (HSPB6) Regulates Transforming Growth Factor- β -Induced Migration and Invasion of Hepatocellular Carcinoma Cells.	PLoS One.	11(4)	e0151907	2016	
76)	Lin SY, Toyoda H, <u>Kumada T</u> , Liu HF. Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan.	Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan.	PLoS One.	11(6)	e0157103.	2016	
77)	Tada T, <u>Kumada T</u> , Toyoda H, Tsuji K, Hiraoka A, <u>Tanaka J</u> .	Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in CHB patients: an analysis using time-dependent ROC.	J Gastroenterol Hepatol.	Epub ahead of print		2016	
78)	Hiraoka A, <u>Kumada T</u> , Nouse K, Tsuji K, Itobayashi E, Hirooka M, Kariyama K, Ishikawa T, Tada T, Toyoda H, Kawasaki H, Hiasa Y, Michitaka K.	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.	Oncology	91(3)	153-61.	2016	
79)	Takada K, Ito T, <u>Kumada T</u> , Toyoda H, Tada T, Sone Y, Endo T, Tanaka K, Kitagawa H, Ichikawa K.	Extra-hepatic feeding arteries of hepatocellular carcinoma: An investigation based on intra-arterial CT aortography images using an angio-MDCT system.	Eur J Radiol.	85(8)	1400-6.	2016	
80)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Viral Eradication reduces all-Cause Mortality, Including non-Liver-Related Disease, in Patients With Progressive Hepatitis C Virus-Related Fibrosis.	J Gastroenterol Hepatol.	Epub ahead of print		2016	
81)	Toyoda H, Tada T, Tachi Y, Hirai T, Yasuda S, Honda T, Hayashi K, Ishigami M, Goto H, <u>Kumada T</u>	Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.	Antivir Ther.	Epub ahead of print		2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
82)	Toyoda H, <u>Kumada T</u> , Tada T.	Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.	Hepatol gy.	64(5)	1818- 1819.	2016	
83)	Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Tachi Y, Ishikawa T, Katano Y, Yoshioka K, Toyoda H, <u>Kumada T</u> , Goto H, Hirooka Y.	Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.	J Gastroen terol.	51(11)	1081- 1089	2016	
84)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Post-treatment levels of -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.	Hepatol Res.	Epub ahead of print		2016	
85)	Toyoda H, <u>Kumada T</u> , Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T.	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.	J Hepatol.	Epub ahead of print		2016	
86)	Toyoda H, Tada T, Takaguchi K, Senoh T, Shimada N, Hiraoka A, Michitaka K, Ishikawa T, <u>Kumada T</u> .	Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.	J Viral Hepat.	Epub ahead of print		2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
87)	Honda T, Ishigami M, Ishizu Y, Kuzuya T, Hayashi K, Ishikawa T, Murakami Y, Iwadate M, Umeyama H, Toyoda H, <u>Kumada T</u> , Katano Y, Goto H, Hirooka Y.	The Core I97L mutation in conjunction with P79Q is associated with persistent low HBVDNA and HBs antigen clearance in chronic hepatitis B patients.	Clin Microbiol Infect.	Epub ahead of print		2016	
88)	Aoki T, Iijima H, Tada T, <u>Kumada T</u> , Nishimura T, Nakano C, Kishino K, Shimono Y, Yoh K, Takata R, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S.	Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases.	J Gastroenterol.	52(1)	104-112	2017	
89)	Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, <u>Kumada T</u> .	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.	Br J Cancer.	Epub ahead of print		2017	
90)	豊田 秀徳, <u>熊田 卓</u> , 多田 俊史	目指せ!C型肝炎ウイルスの克服-肝がん制圧に向けての更なる挑戦-】あくなき議論!高齢者は何歳まで治療すべきか? 発癌リスク・生命予後・費用対効果の観点から、	肝臓クリニカルアップデート	2巻1号	Page45-50	2016	
91)	多田 俊史, <u>熊田 卓</u> , 豊田 秀徳, 水野 和幸	肝硬変のマネジメント-その進歩と課題-】C型肝炎に対する抗ウイルス療法 肝不全・肝癌への進展をどう抑制するか、	消化器の臨床	19巻3号	Page209-215	2016	
92)	<u>熊田 卓</u>	【こむら返りと漢方】こむら返りに対する芍薬甘草湯の効果	漢方と最新治療	25巻2号	Page91-95	2016	
93)	平岡 淳, <u>熊田 卓</u> , 系林 詠, 辻 邦彦, 石川 達, 広岡 昌史, 狩山 和也, 能祖 一裕, 多田 俊史, 豊田 秀徳, 日浅 陽一, 道堯 浩二郎	新しい肝予備能評価・albumin-bilirubin(ALBI)-gradeを用いた肝癌ラジオ波治療における予後予測 JISスコア変法・ALBI-Tスコアの有用性	肝臓	57巻7号	Page312-319	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
94)	豊田 秀徳, 熊田 卓	【C型肝炎 SVR 後の肝発 癌】 C型肝炎 SVR 症例の 長期予後	医学のあ ゆみ	259 巻 4 号	Page28 7-291	2016	